drugset
drugset / Trial / NCT01236443

Study of Photodynamic Therapy (PDT) Using HPPH in Barrett's Esophagus

NCT01236443 ↗

Phase 1 Completed 18 enrolled Roswell Park Cancer Institute
NaSingle-groupOpen-labelTreatment

Summary

A Study to identify toxicity and optimal photodynamic treatment parameters using the photosensitizer 2-\[1-hydroxyethyl\]-2-devinylpyropheophorbide-a (HPPH) in high grade dysplasia, carcinoma-in-situ, or early adenocarcinoma in Barrett's esophagus.

Timeline

Start
2000-08
Primary completion
2003-05
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Subject 2-(1-HEXYLOXYETHYL)-2-DEVINYL PYROPHEOPHORBIDE-A Unknown 3 mg/m2 Intravenous

Indications

Barrett esophagus intraepithelial neoplasia